MYEZOM 2 MG

Across the clinical settings represented in this database, Bortezomib is associated with Multiple myeloma; mantle cell lymphoma in selected settings. Its pharmacology is summarized by the fact that it reversibly inhibits the 26S proteasome, causing accumulation of proteins and apoptosis in susceptible plasma cells. Proteasome inhibition targets a cellular process on which malignant plasma cells and selected lymphoid tumors can be particularly dependent. The medicine is classified as Targeted Therapy; Proteasome Inhibitor and belongs to the 26S proteasome inhibitor group. The associated tumor types are Multiple Myeloma; Mantle Cell Lymphoma, while the documented regimen examples are VRd; CyBorD/VCd; Dara-VRd; R-CHOP variants; bortezomib-based myeloma regimens. These details place the agent within specific treatment pathways rather than describing a generalized use across oncology. Molecular and disease-specific eligibility can therefore be more important than tumor location alone when the treatment is considered. Any selection criterion explicitly included in the indication—whether molecular, receptor-based, disease-stage related, or dependent on prior therapy—should be retained when interpreting the record. Related agents may have overlapping indications but still differ in target or clinical positioning. This description is intended for professional reference and avoids individualized prescribing recommendations. Current labels and disease-specific guidelines should be consulted because accepted uses can change with new evidence and regulatory updates.